UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy

International journal of molecular sciences, 2020-10, Vol.21 (19), p.7358

2020

Volltextzugriff (PDF)

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting

International journal of molecular sciences, 2020-10, Vol.21 (21), p.8004

2020

Volltextzugriff (PDF)

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial

Clinical cancer research, 2016-10, Vol.22 (19), p.4786-4796

2016

Volltextzugriff (PDF)

Capecitabine therapy of central nervous system metastases from breast cancer

Journal of neuro-oncology, 2007-11, Vol.85 (2), p.223-227

2007

Volltextzugriff (PDF)

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report

BMC cancer, 2020-01, Vol.20 (1), p.47-8, Article 47

2020

Volltextzugriff (PDF)

Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement

BMC cancer, 2016-11, Vol.16 (1), p.842-842, Article 842

2016

Volltextzugriff (PDF)

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma

Clinical cancer research, 2014-10, Vol.20 (19), p.5023-5031

2014

Volltextzugriff (PDF)

The future of cancer immunotherapy for brain tumors: a collaborative workshop

Journal of translational medicine, 2022-05, Vol.20 (1), p.236-236, Article 236

2022

Volltextzugriff (PDF)

QOL-22. USE OF TUMOR TREATING FIELDS THERAPY WITH ADJUVANT TEMOZOLOMIDE AND IMMUNOTHERAPY FOR NEW DIAGNOSED GLIOBLASTOMA (NDGBM)

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v253-v254

2023

Volltextzugriff (PDF)

Characterization of central nervous system multiple myeloma in the era of novel therapies

Leukemia & lymphoma, 2016-07, Vol.57 (7), p.1709-1713

2016

Volltextzugriff (PDF)

ATIM-20. A RETROSPECTIVE STUDY EVALUATING THE SAFETY AND SURVIVAL OF THE COMBINATION OF PD-1 IMMUNE CHECKPOINT BLOCKADE AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi5-vi5

2019

Volltextzugriff (PDF)

Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice

Nature medicine, 2010-05, Vol.16 (5), p.598-602

2010

Volltextzugriff (PDF)

Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting

International journal of molecular sciences, 2020-07, Vol.21 (15), p.5278

2020

Volltextzugriff (PDF)

Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma

Journal of clinical oncology, 2006-10, Vol.24 (28), p.4570-4574

2006

Volltextzugriff (PDF)

Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma

Journal of neuro-oncology, 2016-06, Vol.128 (2), p.241-250

2016

Volltextzugriff (PDF)

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3861-3867

2009

Volltextzugriff (PDF)

YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

Clinical cancer research, 2006-10, Vol.12 (19), p.5698-5704

2006

Volltextzugriff (PDF)

Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2023-06, Vol.72 (6), p.1893-1901

2023

Volltextzugriff (PDF)

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

The New England journal of medicine, 2023-08, Vol.389 (7), p.589-601

2023

Volltextzugriff (PDF)

Abstract CT062: A Phase I study of the safety and immunogenicity of personalized mutation-derived tumor vaccine and treatment fields in patients with newly diagnosed glioblastoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT062-CT062

2019

Volltextzugriff (PDF)

Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma

American journal of roentgenology (1976), 2018-01, Vol.210 (1), p.18-23

2018

Volltextzugriff (PDF)

Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (11), p.1658-1666

2020

Volltextzugriff (PDF)

Abstract CT231: Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT231-CT231

2020

Volltextzugriff (PDF)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma

Frontiers in oncology, 2014-01, Vol.4, p.90-90

2014

Volltextzugriff (PDF)

A target for antiangiogenic therapy: Vascular endothelium derived from glioblastoma

Proceedings of the National Academy of Sciences - PNAS, 2011-03, Vol.108 (11), p.4271-4272

2011

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(79)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial

Capecitabine therapy of central nervous system metastases from breast cancer

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report

Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma

The future of cancer immunotherapy for brain tumors: a collaborative workshop

QOL-22. USE OF TUMOR TREATING FIELDS THERAPY WITH ADJUVANT TEMOZOLOMIDE AND IMMUNOTHERAPY FOR NEW DIAGNOSED GLIOBLASTOMA (NDGBM)

Characterization of central nervous system multiple myeloma in the era of novel therapies

ATIM-20. A RETROSPECTIVE STUDY EVALUATING THE SAFETY AND SURVIVAL OF THE COMBINATION OF PD-1 IMMUNE CHECKPOINT BLOCKADE AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA

Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice

Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting

Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma

Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Abstract CT062: A Phase I study of the safety and immunogenicity of personalized mutation-derived tumor vaccine and treatment fields in patients with newly diagnosed glioblastoma

Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma

Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors

Abstract CT231: Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma

A target for antiangiogenic therapy: Vascular endothelium derived from glioblastoma

Suchergebnisse filtern